Recombinant PDCD1 (Camrelizumab Biosimilar) 抗体
This Humanized 单克隆 antibody specifically detects PDCD1 (Camrelizumab Biosimilar) in FACS 和 in vivo. It exhibits reactivity toward 人.
产品编号 ABIN7795091
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant PDCD1 (Camrelizumab Biosimilar) 抗体 (ABIN7795091)
抗原
PDCD1 (Camrelizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This PDCD1 (Camrelizumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Camrelizumab Biosimilar, PD-1 Monoclonal Antibody
-
产品特性
- Camrelizumab Biosimilar uses the same protein sequences as the therapeutic antibody camrelizumab. Camrelizumab is an IgG4κ humanized monoclonal antibody being investigated for hepatocellular carcinoma. It targets programmed cell death protein 1 (PD-1), a protein on the surface of cells, also known as CD279 (cluster of differentiation 279). Camrelizumab is being evaluated in the Phase 2/3 (NCT02989922) of patients with advanced hepatocellular carcinoma (HCC) in second-line after failure or intolerance to prior systemic treatment. The study has 2 arms in which patients will be intravenous administered 3 mg/kg SHR-1210 on day 1 every 2 weeks or every 3 weeks. The primary outcome measures are the overall response rate (ORR) and overall survival (OS) rates at 6 months with duration of response and OS at 2 years as secondary endpoints. The estimated enrollment is 220 patients, and the estimated primary completion date is December 2018. A randomized, open-label Phase 3 study (NCT03099382) is evaluating the efficacy of camrelizumab treatment compared to standard-of-care treatment (docetaxel or irinotecan) in patients with esophageal carcinoma. Patients are randomly assigned to receive either SHR-1210 (200 mg every 2 weeks) or the standard of care (docetaxel 75 mg/m2 on day 1 every 3 weeks or irinotecan 180 mg/m2 on day 1 every 2 weeks). This Phase 3 study has an estimated enrollment of 438 and an estimated primary completion date of June 2018.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human PD1
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- PDCD1 (Camrelizumab Biosimilar)
-
别名
- Camrelizumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
